drugset / Trial / NCT00673868

Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants

NCT00673868 ↗

Phase 1 Completed 2 enrolled Milton S. Hershey Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This study examines the immunologic and virologic effects of prophylactic CMV specific CTL in recipients of T cell depleted stem cell transplant (TCD SCT) at Duke University Medical Center (DUMC), by measuring levels of CMV DNA and virus specific T cell precursors at intervals post-infusion.

Timeline

Start
2007-10
Primary completion
2008-08-06
Completion
2008-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CMV Specific Cytotoxic T Lymphocytes Cell therapy 200000 cells/kg —
Subject CMV Specific Cytotoxic T Lymphocytes Cell therapy 500000 cells/kg —